Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
Abstract Case Approximately 3%‐25% of cases of endometrial carcinoma (EC) or atypical endometrial hyperplasia (AH) occur in women aged <40 years and conservative treatment with high‐dose medroxyprogesterone acetate (MPA) is administered to women who wish to preserve their fertility. Here is repor...
Główni autorzy: | Toshiya Matsuzaki, Takeshi Iwasa, Takako Kawakita, Yuri Yamamoto, Akiko Abe, Aki Hayashi, Kiyohito Yano, Masato Nishimura, Akira Kuwahara, Minoru Irahara |
---|---|
Format: | Artykuł |
Język: | English |
Wydane: |
Wiley
2018-07-01
|
Seria: | Reproductive Medicine and Biology |
Hasła przedmiotowe: | |
Dostęp online: | https://doi.org/10.1002/rmb2.12209 |
Podobne zapisy
-
Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
od: Vakkas Korkmaz, i wsp.
Wydane: (2013-08-01) -
Results of surgical treatment of atypical endometrial hyperplasia
od: O. A. Gornykh, i wsp.
Wydane: (2014-07-01) -
Modern approaches to the diagnosis of endometrial hyperplasia
od: M. M. Damirov, i wsp.
Wydane: (2025-02-01) -
Microsatellite instability as a reliable marker of coexisting endometrial cancer in atypical endometrial hyperplasia
od: А. E. Protasova, i wsp.
Wydane: (2024-07-01) -
Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer
od: An-Ju Chou, i wsp.
Wydane: (2024-11-01)